Summary 9gmTc-sestamibi (SSmTc-MIBI) is a substrate for the P-glycoprotein (P-gp) pump but it is not known whether it is a substrate for the multidrug resistance-associated protein (MRP) pump. Therefore, 99mTc-MIBI was evaluated in the GLC4 cell line and its doxorubicin-resistant MRP-, but not P-gp-, overexpressing GLC4/ADR sublines as well as in the Si cell line and its MRP-transfected subline Sl-MRR 99mTc-MIBI concentration decreased in the GLC4/ADR sublines with increasing MRP overexpression and was lower in S1-MRP than in Si. 99mTc-MIBI plus vincristine increased 99mTc-MIBI concentration in GLC4 lines compared with 99,"Tc-MIBI alone. 99,"Tc-MIBI efflux raised with increasing MRP expression in the GLC4 lines. Glutathione depletion elevated 99mTc-MIBI concentration in GLC4/ADR15,x. Cross resistance for 99Tc-MIBI, used to test cytotoxicity of the Tc compound, was observed in GLC4/ADR,50X vs GLC4. 99Tc-MIBI induced a synergistic effect on vincristine cytotoxicity in GLC4/ADR15oX. These results show that 99mTc-MIBI is involved in MRP-mediated efflux. The fact that 99mTc-MIBI efflux is influenced by MDR1 and MRP expression must be taken into account when this y-rays-emitting complex is tested for tumour efflux measurements.
Resistance of tumours to chemotherapeutic compounds is an important problem in the clinic. Drugs such as anthracyclines, vinca alkaloids and epipodophyllotoxins are involved in the socalled multidrug resistance (MDR) Bradley et al, 1988 ; De Vries et al, 1989 ; De Jong et al, 1990; Meijer et al, 1990; Cole et al, 1992; Versantvoort et al, 1992; Scheper et al, 1993) .
One of the mechanisms involved in MDR is the overexpression, in tumour cells, of the ATP-dependent 170-kDa P-glycoprotein (P-gp) encoded by the MDR] gene (Endicott and Ling, 1989) . P-gp acts as a transmembrane efflux pump that transports chemotherapeutic compounds out of the cell, resulting in drug resistance. P-gp is also expressed in many normal human tissues, such as the liver (bile canaliculi), pancreas, colon, jejunum and kidney (Thiebaut et al, 1987; Sugawara et al, 1988) . In normal tissues, P-gp is considered to act as a transporter of toxins.
Drugs that are substrates for P-gp are hydrophobic and mostly positively charged at neutral pH. Piwnica-Worms et al (1993) have shown that 99mTc-sestamibi (99mTc-MIBI), a lipophilic cationic radiopharmaceutical, is also a substrate for P-gp-mediated transport (Piwnica-Worms et al, 1993; Vallabhaneni et al, 1994; Ballinger et al, 1995) . Consequently, 99-Tc-MIBI allowed visualization of P-gp-mediated efflux in tumours in the animal model (Piwnica-Worms et al, 1993) .
Apart from P-gp, another pump, the multidrug resistance-associated protein (MRP), is involved in MDR. The MRP pump was identified and characterized as a member of the ATP-binding cassette superfamily (Cole et al, 1992; Ishikawa, 1992; Jedlitschky et al, medium , fetal calf serum (FCS) and geneticin were purchased from Gibco (Paisley, UK), D,L-buthionine S,R-sulphoximine (BSO) and 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) from Sigma (St Louis, MD, USA), Dulbecco's modified Eagle medium (DMEM) and HAM F12 medium from Flow Laboratories (Irvine, UK).
Solid NH4 99TcO4 was kindly provided by Dr Hector Knight (Mallinkrodt Medical, Petten, The Netherlands) and Cardiolite vials by Dr Stephen Haber (Du Pont Merck, Billerica, MA, USA). 99mTc-MIBI was synthesized with a one-step Cardiolite kit formulation containing 0.075 mg of solid stannous chloride as a reducing agent for technetium (Tc) and excess hexakis (2-methoxyisobutyl isonitrile) (MIBI) as the Cu(MIBI)4BF4 salt. A total of 10-12 GBq [99mTc]TcO4-obtained from a commercial molybdenum/Tc generator (Ultra-TechneKowFM) was added to the kit reaction vial, heated at 100°C for 10 min and allowed to cool to room temperature. Radiochemical purity was > 98% by thin-layer chromatography (Gelman Sciences, Ann Arbor, MI, USA) with 0.9% sodium chloride as mobile phase. In addition, macroscopic quantities of 99Tc-MIBI for cytotoxicity experiments were prepared by the reaction of NH499TcO4 with Cardiolite vials. Solid NH499TcO4 (100 mg, 0.55 mmol) was dissolved in 2 ml of 0.9% sodium chloride, filtered and thereafter diluted with 0.9% sodium chloride until a final volume of 5 ml. As 99Tc-MIBI is a W-emitter (t12 = 2.1 x 105 a, P-0.3 MeV), this stock solution was calibrated using a ,-counter (Packard Instruments, Downers Grove, IL, USA). A Cardiolite kit was dissolved in 0.65 ml of stannous chloride solution (8.4 gmol ml Sn2+). Thereafter, 37 MBq Na99mTcO4 eluate and 15 gl of the NH499TcO4 stock solution (1.1 Igmol, 0.2 mg) was added. The kit reaction vial was heated at 100°C for 15 min and allowed to cool to room temperature, producing an almost quantitative yield of the 99Tc(MIBI)6+ complex. The reaction mixture was loaded onto a C-18 Sep Pak cartridge (Waters Associates, Milford, MA, USA). The Sep Pak cartridge was pre-wet with 5 ml of ethanol, followed by a 10-ml water rinse. The cartridge was washed with 10 ml of 0.9% sodium chloride and the pure complex was eluted with ethanoll0.9% sodium chloride (95:5.5 ml). The radiochemical purity was > 97% by thin-layer chromatography. The chemical structure was confirmed by ion-spray mass spectrometry (Nermag, Argenteuil, France). This yielded a single peak at m/z = 777 with characteristic major fragments at 664 (99Tc-MIBI5)+ and 551 (99Tc-MIBI4)+. The solution was evaporated (37°C, under a nitrogen atmosphere). 99Tc-MIBI6Cl was dissolved in ethanoll0.9% sodium chloride 1:9 (v/v). The solution was calibrated using the abovementioned 1-counter. The final concentrations of the different solutions were between 3 and 7 mM 99Tc-MIBI. In addition, to avoid ethanolinduced effects in 99Tc-MIBI cytotoxicity experiments, the stock solution of 99Tc-MIBI in ethanol was diluted to 300 gM 99Tc-MIBI as the highest concentration (< 1% ethanol in the MTA controls).
Cell lines
The human ovarian cancer cell line, A2780 and its 92-fold doxorubicin-resistant MDRI-overexpressing but MRP-negative subline A2780AD were cultured in RPMI 1640 medium/10% FCS in a humidified atmosphere with 5% carbon dioxide at 37°C (Zijlstra et al, 1987) . Stable resistance in the A2780AD cell line was assured by culturing this line with 2 gM doxorubicin twice a week. Before use, A2780AD was cultured without doxorubicin for 14 days.
The human small-cell lung cancer cell line GLC4 and its doxorubicin-resistant MRP overexpressing, P-gp-negative sublines GLC4/ADR2x, GLC4/ADR1Ox and GLC4/ADR150X with two-fold, 10-fold and 150-fold resistance, respectively, to doxorubicin were cultured in RPMI 1640 medium/10% FCS in a humidified atmosphere with 5% carbon dioxide at 37°C (Zijlstra et al, 1987; De Jong et al, 1990; Meijer et al, 1991; Versantvoort et al, 1995a ). GLC4 expresses a low level of MRP. MRP mRNA was overexpressed in all GLC4-resistant sublines with a higher expression with increasing doxorubicin resistance (Muller et al, 1994) . Resistance to doxorubicin in these resistant cell lines was assured by culturing GLC4/ADR2. and GLC4/ADR,IX, respectively, with 0.018 gM and 0.59 gM doxorubicin once every 3 weeks and GLC4/ADR 15M with 1.2 gM doxorubicin twice a week. Before use, the resistant cell lines were cultured without doxorubicin for 21 days. In addition, on a regular basis, mdrl-RNA expression and P-gp expression were characterized in GLC4 and GLC4 sublines. Both were always negative.
The human non-small-cell lung cancer cell line SW-1573/S1 and its stable MRP-overexpressing subline S 1-MRP were kindly provided by Professor Dr P Borst and Dr G Zaman, Dutch Cancer Institute, Amsterdam, The Netherlands. They were cultured in DMEM medium/10% FCS in a humidified atmosphere with 5% carbon dioxide at 37°C. The MRP-overexpressing cell line was obtained after transfection of SW-1573/S1 cells with an expression vector containing MRP cDNA and a neo gene (pRc/RSV-MRP), followed by selection with geneticin . In addition, the MRP expression was negative in SI and positive in S1-MRP. Cellular 99mTc-MIBI accumulation and efflux Cells (2 x 106) from A2780, GLC4, S1 and their resistant sublines were incubated in polystyrene tubes for 1 h at 370C with 64 fm 99mTc-MIBI in 5 ml of RPMI 1640/10% FCS. The different cells lines were initially incubated with 99mTc-MIBI for 15 min and 1 h. Because the steady state of 99mTc-MIBI was reached within 1 h of incubation, further experiments were performed with 1-h drug incubation. To study modulating effects, A2780 and its resistant subline were incubated simultaneously with 99mTc-MIBI (64 fM) and verapamil (50 JM), and GLC4 and its resistant sublines were experiments, each performed in duplicate. Compared with 99mTc-MIBI alone, the cellular "mTc-MIBI concentration plus vincristine as well as the cellular 99mTc-MIBI concentration after pretreatment with BSO was higher in GLC4 (P < 0.0005), GLC4/ADR2, (P < 0.0005), GLC4/ADR1O1 (P < 0.0005) and GLC4/ADR15,X (P < 0.0005) incubated with 99mTc-MIBI (64 fM) and vincristine (20 gM) for 1 h.
After the incubation, the cells were washed with 5 ml of ice-cold phosphate-buffered saline (PBS) followed by centrifugation (5 min, 180 g, 40C). The wash step as described above was repeated three times. The cellular 99mTc-MIBI was measured in water with a y-counter (LKB Wallac, Turku, Finland) . Correction of the extracellular adhesion of 99mTc-MIBI to the cells was performed by subtracting the results obtained after 99mTc-MIBI incubation for 5 min at 40C. Extracellular adhesion of 99mTc-MIBI was always less than 5% compared with the cellular accumulation of 99mTc-MIBI. The cellular accumulation was expressed as attomol 99-Tc-MIBI per 106 cells. For efflux studies, 2 x 106 cells from these cell lines were incubated in 5 ml of RPMI 1640/10% FCS for 1 h at 370C with 64 fM 99,Tc-MIBI as described above. Thereafter, the cells were washed with RPMI 1640/10% FCS at 370C. After 0, 10 or 30 min, the efflux of 99mTc-MIBI was terminated by adding ice-cold PBS followed by centrifugation (5 min, 180 g, 4°C) and measurement of the cellular 99mTc-MIBI. After correction for extracellular adhesion of 99-Tc-MIBI, efflux was expressed as % 99mTc-MIBI in the cells related to the amount of 99mTc-MIBI after 1 h of 99mTc-MIBI incubation. Three to six independent experiments were performed, each in duplicate.
To check the effect of difference in cellular 99mTc-MIBI accumulation on cellular efflux of 99mTc-MIBI, 2 x 106 cells from GLC4 and GLC4/ADR 10, were incubated with 8 MBq (64 fM). Because accumulation of 99-Tc-MIBI was found to be four fold higher in GLC4, than in GLC4/ADR150x , GLC4 and GLC4/ADR150x were incubated at 4°C for 1 h with 8 MBq (64 fM) and 2 MBq (16 fM) respectively. After incubation with 99mTc-MIBI at equal levels, the efflux study was started as described above at a temperature of 370C.
The effect of glutathione depletion on 99mTc-MmBI accumulation was analysed in GLC4 and GLC4/ADR_,^O. Cells were precultured for 24 h in the presence of 25 JM of the glutathione synthesis inhibitor BSO. After 24 h, glutathione is no longer detectable in these lines, without growth delay or loss of viability (Meijer et al, 1991) . After 24 h, the cell lines were incubated for 1 h with 9"mTc-MIBI as described above. Three independent experiments were performed, each in duplicate.
Cytotoxicity assay
The microculture tetrazolium assay (MTA) was used as described before (Steel and Peckham, 1979) . Cells, 3750 and 10 000 per well for GLC4 and GLC4/ADR150X, respectively, were incubated for 1 h with 99Tc-MIBI in a concentration range from 0.5 JM to 300 gM in 0.1 ml of culture medium. Thereafter, the cells were washed three times by removal of medium after centrifugation (10 min, 180 g) followed by addition of fresh medium and were cultured for 4 days. The percentage cell survival was calculated as the mean of test samples/mean of untreated samples. Controls consisted of media without cells (background extinction) and cells incubated with medium instead of the drug. Two independent experiments were performed, each in quadruplicate. From these survival curves, the 99Tc-MIBI concentrations were determined that inhibited cell survival by 10% (ICIO) or 25% (IC25).
IC1o and IC25 concentrations of 99Tc-MIBI were used to test the modulating effect of 99Tc-MIBI on vincristine cytotoxicity in GLC4 and GLC4/ADR1,50x. Survival curves were performed in GLC4 and GLC4/ADR150. cell lines for 1-h exposure to vincristine (range 0 JM to 0.60 JM) plus and minus 99Tc-MIBI (ICIO or IC25).
Modulating effects were analysed by isobologram analysis according to Steel and Peckman (1979) . Three independent experiments were performed, each in quadruplicate.
Statistics
Statistical significance was determined with the paired and unpaired Student's t-test. Only P-values < 0.05 were considered to be significant. (0) and S1-MRP (0) cells. CDmTc-MIBI content was determined after 1-h drug exposure and at 10 min and 30 min with drug-free medium and expressed as a % of the radioactivity present after 1-h drug exposure. Each point represents the mean ± s.d. of three independent experiments, each performed in duplicate. At t = 10 min, the cellular 99mTc-MIBI concentration was lower in S1-MRP than in S1 (P < 0.0025) attomol per 106 cells in the MRP-transfected cell line S1-MRP and 0.43 ± 0.24 attomol per 106 cells in its parental cell line. Exposure to 99mTc-MIBI plus vincristine increased the cellular 99mTc-MIBI concentration significantly compared with 99mTc-MIBI exposure alone (Figure 2 ). In the GLC4 sublines, the percentage of 99mTc-MIBI efflux coincided with increase in doxorubicin resistance. Ten minutes after starting the efflux study, the cellular 99mTc-MIBI concentration was 76% in GLC4/ADR2X, 66% in GLC4/ADR1ox and 49% in GLC4/ADR150x compared with GLC4 (Figure 3) . In Si-MRP, the efflux was also increased compared with S 1. The cellular 99-Tc-MIBI concentration after 10 min in drug-free medium was 39% in S1-MRP and 61% in SI (Figure 4) . Glutathione depletion by BSO followed by 1 h of 99mTc-MIBI exposure increased the 99mTc-MIBI concentration in GLC4 to 182% compared with undepleted GLC4 cells. In glutathionedepleted GLC4/ADR 150 cells, the 99mTc-MIBI concentration increased even more. This increase resulted in a cellular 99mTc-MIBI concentration that differed, no longer significantly, from the cellular 99-Tc-MIBI concentration in GLC4 (Figure 2 ).
RESULTS

Cell survival
Cell survival curves of GLC4 and GLC4/ADR5,OX cell lines after exposure to 99Tc-MIBI are shown in Figure 5 . Over the 99Tc-MIBI concentration range tested, more cytotoxicity was observed in GLC4 than in GLC4/ADR150x. The 99Tc-MIBI IC1O and IC25 were 50 gIM and 85 gIM, respectively, for GLC4 and 100 gM and > 300 gIM, respectively, for GLC4/ADR 15x. A modulation effect of 99Tc-MIBI (IC1O and IC25) was observed on vincristine cytotoxicity in GLC4/ADR 150, but not in GLC4. Isobologram analysis showed a synergistic effect of 99Tc-MIBI on vincristine cytotoxicity in GLC4/ADR151, (data not shown).
DISCUSSION
The present study demonstrates that in vitro 99mTc-MIBI is not only a substrate for P-gp but also for MRP. The earlier results of PiwnicaWorms et al (1993) , which suggest that 99mTc-MIBI is a substrate for P-gp, were confirmed. Co-incubation of 99mTc-MLBI and verapamil resulted in an increased cellular concentration of 99mTc-MIBI in the P-gp-overexpressing cell line A2780AD, while no effect was observed in the doxorubicin-sensitive parental cell line.
Evidence that 99mTc-MIBI is also a substrate for MRP has been obtained along various lines. In sublines of the human small-cell lung carcinoma cell line GLC4, with varying degrees of doxorubicin resistance and MRP content, it was shown that 99mTc-MIBI accumulation was lower when MRP expression increased. Versantvoort et al (1995a) (1998) 77(3), 353-358 n these cell lines was also shown to correlate with increased 99mTc-MIBI efflux. In addition, incubation of GLC4 and GLC4/ADRl5Ox with 99mTc-MIBI at 4°C to reach equal accumulation in absolute terms confirmed increased 99mTc-MIBI efflux with increased MRP expression. This indicates that 99mTc-MIBI efflux is not dependent on the absolute cellular levels of 99mTc-MIBI, but efflux is dependent on the rate of transport per minute. Co-incubation of 99mTc-MIBI with vincristine resulted in higher 99mTc-MIBI levels in all GLC4 cell lines. The fact that 99mTc-MIBI also increased by vincristine co-incubation in the parental GLC4 cell line can be explained by a low MRP expression in this cell line. The effects of vincristine are most likely due to partial blocking of 99mTc-MIBI efflux by vincristine. Doxorubicin resistance in GLC4/ADR 150x is multifactorial and considered to be due to an increase in MRP, an increased detoxification and decreased DNA topoisomerase II level (Zijlstra et al, 1987; Timmer-Bosscha et al, 1989; Simon et al, 1994) . Therefore, we also analysed the effect of 99mTc-MIBI on the non-small-cell lung carcinoma cell line SI and its MRP-transfected subline S1-MRP. Just as in the GLC4 cell lines, a lower accumulation and increased efflux of 99mTc-MIBI was observed in SI -MRP compared with the parental SI cell line.
Recently, it was shown that MRP functions as a glutathione Sconjugate carrier Leier et al, 1994; Muller et al, 1994) . This finding has stimulated studies with MDR drugs in MRP-overexpressing cell lines after glutathione depletion with BSO (Meijer et al, 1991; Versantvoort et al, 1995b; Zaman et al, 1995) . Zaman et al (1995) observed a complete reversal of resistance to doxorubicin, daunorubicin, vincristine and etoposide after glutathione depletion in the MRP-transfected cell line S1-MRP. Glutathione depletion also resulted in an increased 99-Tc-MIBI accumulation from MRP-transfected cells. These BSO effects were not observed in P-gp-overexpressing cell lines (Versantvoort et al, 1995b) . In the present study, it was shown that glutathione depletion in GLC4/ADR15ox almost fully restored the cellular 99mTc-MIBI level to the level obtained in GLC4. In addition, evaluation of the enhancing effects of 99Tc-MIBI on vincristine cytotoxicity with isobologram analysis according to Steel and Peckman (1979) demonstrated that the blocking effects of 99Tc-MIBI on vincristine cytotoxicity in GLC4/ADRl5OX is synergistic. Cytotoxicity testing revealed cross-resistance for 99Tc-MIBI between GLC4/ADR 150x and GLC4. The increased 99mTc-MIBI efflux, the effects of glutathione depletion on cellular 99mTc-MIBI levels and the crossresistance for 9Tc-MIBI as well as increased cytotoxicity of vincristine induced by 99Tc-MIBI in MRP-overexpressing cells indicate that Tc-MIBI is a substrate for MRP. Tc-MIBI seems to behave in a way similar to that of the chemotherapeutic drugs involved in MRP-mediated MDR. Glutathione S-conjugates are transported by MRP (Ishikawa, 1992) and, based on experiments with inside-out vesicles, it is suggested that only substrates with a hydrophobic part and at least two negative charges can be transported by MRP. There is still much debate in the literature on how doxorubicin and vincristine are transported by MRP (Versantvoort et al, 1995b; Zaman et al, 1995) . For these chemotherapeutic drugs, no glutathione S-conjugates have been identified. One possibility might be that these conjugates are unstable and therefore not detectable. Another hypothesis is that the chemotherapeutic drugs are co-transported with glutathione by the MRP pump Leier et al, 1994; Muller et al, 1994; Zaman et al, 1995). 99mTc-MIBI is a synthetic 7y-ray-emitting organotechnetium complex. In vitro, it is a substrate for both P-gp and MRP. Therefore, it might be used in vivo for functional efflux imaging in tumours. Efflux of 99-Tc-MIBI could then be extrapolated to the efflux of chemotherapeutic agents. This is of potential interest as it is known that in drug-resistant cells both P-gp and MRP can be overexpressed at the same time (Brock et al, 1995; Schuurhuis et al, 1995) . For P-gp, several blockers are known, such as verapamil and cyclosporin A, which enables the study of the functional efflux inhibition of 99mTc-MIBI by these blockers from P-gp-positive tumours. We are aware of the fact that verapamil and cyclosporin A are not specific inhibitors for P-gp and affect to some extent MRP (Twentyman et al, 1996) . For MRP, it is suggested that probenecid and sulfinpyrazone may be useful as specific reversal agents for MRP-mediated drug resistance (Evers et al, 1996) . Therefore, clinical studies focusing on inhibition of 99mTc-MIBI efflux with such compounds from MRP-positive tumours could be a topic of further investigation. ABBREVIATIONS ATP, adenosine triphosphate; BSO, D,L-buthionine S,R-sulphoximine; DMEM, Dulbecco's modified Eagle medium; DMF, dosemodifying factor; FCS, fetal calf serum; ICIO, drug concentration inhibiting survival by 10%; IC25, drug concentration inhibiting survival by 25%; MDR, multidrug resistance; MRP, multidrug resistance-associated protein; MTA, microculture tetrazolium assay; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; P-gp, P-glycoprotein; PBS, phosphate-buffered saline (0.14 M sodium chloride, 2.7 mm potassium chloride, 6.4 mm disodium hydrogen phosphate, 1.5 mm potassium dihydrogen phosphate, pH 7.4); RPMI 1640, Roswell Park Memorial Institute 1640; Tc, Technetium; 99mTc-MIBI, 99mTc-sestamibi; 99Tc-MIBI, 99Tc-sestamibi.
